OBJECTIVES: The objectives of this study were to investigate cell-free DNA daily concentration changes following an acute myocardial infarction (AMI) and to assess any correlations with complications during hospitalization. METHODS AND RESULTS: Serial cell-free DNA level determinations were performed by quantitative Real-Time PCR in 47 AMI patients once daily during hospitalization (235 samples) and once in 100 healthy subjects. Cell-free DNA concentrations are significantly higher in patients throughout hospitalization compared to healthy subject levels (2.644 (SE 0.0952) vs. 1.519 (SE 0.0566), P < 0.001). The median maximum cell-free DNA concentration was 3.5-fold higher (Mann Whitney P = 0.0035) in 20/47 patients with complicated post AMI course--group I--(1719.7, range 117.32-4996212.1 GenEq/ml plasma) compared with 27/47 patients without complications--group II--(492.9, range 56.43-4715.15 GenEq/ml plasma). Substantial differences exist between cell-free DNA concentrations measured on t(pre) (the day before the complication) and t(c) (the day the complication occurred) as well as t(post) (the day after the complication) in group I whereby cell-free DNA rises significantly in t(c) and remains elevated in t(post) (t(pre) vs. t(c), 2.445 vs. 2.965, P = 0.0171 and t(pre) vs. t(post) 2.445 vs. 2.913, P = 0.023). CONCLUSIONS: Cell-free DNA concentrations were elevated in AMI patients compared to healthy control subjects, rise significantly when complications occur and have a potential clinical value in monitoring patient progress during hospitalization.
OBJECTIVES: The objectives of this study were to investigate cell-free DNA daily concentration changes following an acute myocardial infarction (AMI) and to assess any correlations with complications during hospitalization. METHODS AND RESULTS: Serial cell-free DNA level determinations were performed by quantitative Real-Time PCR in 47 AMI patients once daily during hospitalization (235 samples) and once in 100 healthy subjects. Cell-free DNA concentrations are significantly higher in patients throughout hospitalization compared to healthy subject levels (2.644 (SE 0.0952) vs. 1.519 (SE 0.0566), P < 0.001). The median maximum cell-free DNA concentration was 3.5-fold higher (Mann Whitney P = 0.0035) in 20/47 patients with complicated post AMI course--group I--(1719.7, range 117.32-4996212.1 GenEq/ml plasma) compared with 27/47 patients without complications--group II--(492.9, range 56.43-4715.15 GenEq/ml plasma). Substantial differences exist between cell-free DNA concentrations measured on t(pre) (the day before the complication) and t(c) (the day the complication occurred) as well as t(post) (the day after the complication) in group I whereby cell-free DNA rises significantly in t(c) and remains elevated in t(post) (t(pre) vs. t(c), 2.445 vs. 2.965, P = 0.0171 and t(pre) vs. t(post) 2.445 vs. 2.913, P = 0.023). CONCLUSIONS: Cell-free DNA concentrations were elevated in AMI patients compared to healthy control subjects, rise significantly when complications occur and have a potential clinical value in monitoring patient progress during hospitalization.
Authors: Alexander S Savchenko; Julian I Borissoff; Kimberly Martinod; Simon F De Meyer; Maureen Gallant; Luise Erpenbeck; Alexander Brill; Yanming Wang; Denisa D Wagner Journal: Blood Date: 2013-11-07 Impact factor: 22.113
Authors: Jacqueline F Wang; Xingxiang Pu; Xiaoshan Zhang; Ken Chen; Yuanxin Xi; Jing Wang; Xizeng Mao; Jianhua Zhang; John V Heymach; Mara B Antonoff; Wayne L Hofstetter; Reza J Mehran; David C Rice; Jack A Roth; Boris Sepesi; Stephen G Swisher; Ara A Vaporciyan; Garrett L Walsh; Qing H Meng; Kenna R Shaw; Agda Karina Eterovic; Bingliang Fang Journal: Cancer Date: 2017-11-27 Impact factor: 6.860
Authors: J Czamanski-Cohen; O Sarid; J Cwikel; A Douvdevani; E Levitas; E Lunenfeld; I Har-Vardi Journal: J Assist Reprod Genet Date: 2015-10-05 Impact factor: 3.412